Arcus Biosciences’ (RCUS) Quiet Period To End Tomorrow

Arcus Biosciences’ (NYSE:RCUS) quiet period will end on Tuesday, April 24th. Arcus Biosciences had issued 8,000,000 shares in its initial public offering on March 15th. The total size of the offering was $120,000,000 based on an initial share price of $15.00. During the company’s quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Several research firms recently issued reports on RCUS. Leerink Swann began coverage on Arcus Biosciences in a report on Monday, April 9th. They issued an “outperform” rating and a $21.00 price objective on the stock. Citigroup began coverage on Arcus Biosciences in a report on Monday, April 9th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, Goldman Sachs began coverage on Arcus Biosciences in a report on Monday, April 9th. They issued a “neutral” rating and a $18.00 price objective on the stock.

Shares of Arcus Biosciences stock opened at $16.30 on Monday. Arcus Biosciences has a 1-year low of $13.26 and a 1-year high of $22.10.

In related news, CEO Terry J. Rosen bought 66,666 shares of the stock in a transaction dated Monday, March 19th. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $999,990.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Kathryn E. Falberg bought 30,000 shares of the stock in a transaction dated Monday, March 19th. The shares were bought at an average price of $15.00 per share, for a total transaction of $450,000.00. The disclosure for this purchase can be found here.

TRADEMARK VIOLATION WARNING: “Arcus Biosciences’ (RCUS) Quiet Period To End Tomorrow” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3380546/arcus-biosciences-rcus-quiet-period-to-end-tomorrow.html.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody.

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Favorable Press Coverage Somewhat Unlikely to Affect Horizon Therapeutics  Share Price
Favorable Press Coverage Somewhat Unlikely to Affect Horizon Therapeutics Share Price
ArcBest  Earning Somewhat Favorable News Coverage, Analysis Shows
ArcBest Earning Somewhat Favorable News Coverage, Analysis Shows
Positive Press Coverage Somewhat Unlikely to Affect Mercer International  Stock Price
Positive Press Coverage Somewhat Unlikely to Affect Mercer International Stock Price
Gentherm  VP Sells $31,212.00 in Stock
Gentherm VP Sells $31,212.00 in Stock
Nestle SA  Receives Consensus Recommendation of “Hold” from Analysts
Nestle SA Receives Consensus Recommendation of “Hold” from Analysts
FY2018 EPS Estimates for Valeant Pharmaceuticals International Inc  Lifted by Analyst
FY2018 EPS Estimates for Valeant Pharmaceuticals International Inc Lifted by Analyst


© 2006-2018 Ticker Report. Google+.